Intravascular cells and circulating microparticles induce procoagulant activity via phosphatidylserine exposure in heart failure

[1]  F. Zannad,et al.  Endothelial-driven increase in plasma thrombin generation characterising a new hypercoagulable phenotype in acute heart failure. , 2019, International journal of cardiology.

[2]  J. McMurray,et al.  T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF , 2018, Clinical Research in Cardiology.

[3]  G. Lippi,et al.  Red blood cell distribution width in heart failure: A narrative review , 2018, World journal of cardiology.

[4]  T. Murohara,et al.  Impact of red blood cell distribution width on non-cardiac mortality in patients with acute decompensated heart failure with preserved ejection fraction. , 2017, Journal of cardiology.

[5]  M. Gąsior,et al.  Red blood cell distribution width, relative lymphocyte count, and type 2 diabetes predict all‑cause mortality in patients with advanced heart failure. , 2017, Polish archives of internal medicine.

[6]  J. Mehta,et al.  Role of Inflammation in Heart Failure , 2017, Current Atherosclerosis Reports.

[7]  V. Novakovic,et al.  Enhanced Procoagulant Activity on Blood Cells after Acute Ischemic Stroke , 2017, Translational Stroke Research.

[8]  Jialan Shi,et al.  Microparticles and blood cells induce procoagulant activity via phosphatidylserine exposure in NSTEMI patients following stent implantation. , 2016, International journal of cardiology.

[9]  A. Cohen-Solal,et al.  Non-vitamin K antagonist oral anticoagulants and heart failure. , 2016, Archives of cardiovascular diseases.

[10]  P. Kruzliak,et al.  Circulating endothelial-derived apoptotic microparticles and insulin resistance in non-diabetic patients with chronic heart failure , 2016, Clinical chemistry and laboratory medicine.

[11]  M. Hellmich,et al.  Circulating annexin A5 predicts mortality in patients with heart failure , 2016, Journal of internal medicine.

[12]  G. Lip,et al.  Small-size Microparticles as Indicators of Acute Decompensated State in Ischemic Heart Failure. , 2015, Revista espanola de cardiologia.

[13]  Gregory Y. H. Lip,et al.  Micropartículas de pequeño tamaño como indicadores del estado agudo en la insuficiencia cardiaca sistólica , 2015 .

[14]  M. Sever,et al.  Increased red cell distribution width is associated with poor stem cell mobilization in patients with advanced chronic heart failure , 2015, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[15]  Dominik Spińczyk,et al.  Tissue factor is unregulated in microvascular endothelial cells of patients with heart failure , 2015, Journal of Clinical Pathology.

[16]  A. Berezin,et al.  Predictive value of apoptotic microparticles to mononuclear progenitor cells ratio in advanced chronic heart failure patients. , 2015, Journal of cardiology.

[17]  G. Lippi,et al.  Risk assessment of post-infarction heart failure. Systematic review on the role of emerging biomarkers , 2014, Critical reviews in clinical laboratory sciences.

[18]  J. Bauersachs,et al.  Fractalkine promotes platelet activation and vascular dysfunction in congestive heart failure , 2013, Thrombosis and Haemostasis.

[19]  D. J. Veldhuisen,et al.  Anticoagulation in heart failure: current status and future direction , 2013, Heart Failure Reviews.

[20]  C. O'connor,et al.  Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. , 2013, International journal of cardiology.

[21]  Shunichi Homma,et al.  Warfarin and aspirin in patients with heart failure and sinus rhythm. , 2012, The New England journal of medicine.

[22]  R. Touyz,et al.  Cellular biomarkers of endothelial health: microparticles, endothelial progenitor cells, and circulating endothelial cells. , 2012, Journal of the American Society of Hypertension : JASH.

[23]  C. Gao,et al.  Procoagulant activity of erythrocytes and platelets through phosphatidylserine exposure and microparticles release in patients with nephrotic syndrome , 2012, Thrombosis and Haemostasis.

[24]  C. O'connor,et al.  Thromboembolism and antithrombotic therapy in patients with heart failure in sinus rhythm: current status and future directions. , 2011, Circulation. Heart failure.

[25]  G. E. Gilbert,et al.  Lactadherin functions as a probe for phosphatidylserine exposure and as an anticoagulant in the study of stored platelets , 2011, Vox sanguinis.

[26]  Masaaki Konishi,et al.  Prognostic value of endothelial microparticles in patients with heart failure , 2010, European journal of heart failure.

[27]  D. J. Veldhuisen,et al.  Bone marrow dysfunction in chronic heart failure patients , 2010, European journal of heart failure.

[28]  B. Greenberg,et al.  Depressive Symptoms Are Associated with Soluble P-Selectin Reactivity to Acute Exercise in Heart Failure , 2009, Biological Psychiatry.

[29]  G. Lip,et al.  Soluble, platelet-bound, and total P-selectin as indices of platelet activation in congestive heart failure , 2009, Annals of medicine.

[30]  Mikhail A Panteleev,et al.  Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets , 2007, Thrombosis and Haemostasis.

[31]  G. E. Gilbert,et al.  Lactadherin inhibits enzyme complexes of blood coagulation by competing for phospholipid-binding sites. , 2003, Blood.

[32]  C. O'connor,et al.  Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel? , 2003, American heart journal.

[33]  G. Lip,et al.  Effects of acute exercise on hemorheological, endothelial, and platelet markers in patients with chronic heart failure in sinus rhythm , 2001, Clinical cardiology.

[34]  R H Hruban,et al.  Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. , 2000, The New England journal of medicine.

[35]  G. Lip,et al.  Does heart failure confer a hypercoagulable state? Virchow's triad revisited. , 1999, Journal of the American College of Cardiology.

[36]  S. Frøland,et al.  Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. , 1998, The American journal of cardiology.

[37]  S. Grinstein,et al.  Phosphatidylserine-mediated cellular signaling. , 2013, Advances in experimental medicine and biology.

[38]  G. Lip,et al.  Platelet activation in acute, decompensated congestive heart failure. , 2007, Thrombosis research.

[39]  A. Hoeft,et al.  [Cytokines and heart failure]. , 2004, Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS.

[40]  Paulus Wj.  Cytokines and heart failure. , 2000 .

[41]  T. Drake,et al.  Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. , 1989, The American journal of pathology.